Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ProRoot was a specialized dental biotechnology company primarily known for developing and commercializing Mineral Trioxide Aggregate (MTA), a revolutionary bioactive material used in endodontic procedures. The company's flagship product, ProRoot MTA, became the gold standard for root canal repairs, pulp capping, and apexification due to its superior biocompatibility and ability to promote the regeneration of dental tissues. ProRoot's technology focused on creating a cement-like material that sets in the presence of moisture and provides an effective antibacterial seal while stimulating the formation of new dentin and cementum. The company was eventually acquired by Dentsply Sirona (specifically through its Tulsa Dental Specialties division), which continues to manufacture and market the ProRoot product line globally.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on ProRoot.